Please login to the form below

Not currently logged in
Email:
Password:

rociletinib

This page shows the latest rociletinib news and features for those working in and with pharma, biotech and healthcare.

FDA okays Clovis' Lynparza rival rucaparib

FDA okays Clovis' Lynparza rival rucaparib

The company has been pummelled in recent months after an FDA advisory panel voted against a quick approval of its lung cancer candidate rociletinib, a decision that eventually prompted the company

Latest news

  • FDA panel says no to quick approval of Clovis' rociletinib FDA panel says no to quick approval of Clovis' rociletinib

    FDA panel says no to quick approval of Clovis' rociletinib. Recommends waiting for phase III trial results after "serious" safety concerns. ... An FDA advisory committee all but dashed any hopes that Clovis Oncology had for quick approval of its lung

  • AZ sets price of new lung cancer drug Tagrisso AZ sets price of new lung cancer drug Tagrisso

    The FDA has asked for more data on the drug - called rociletinib - which could potentially hold up the programme by several months. ... The FDA's problems with the dataset for rociletinib hinge on the number of unconfirmed versus confirmed responses to

  • Boehringer takes third-generation NSCLC drug into pivotal trials Boehringer takes third-generation NSCLC drug into pivotal trials

    chemotherapy. Aside from Boehringer, other companies developing third-generation EGFR inhibitors include Clovis Oncology with twice-daily rociletinib (CO-1686) and AZ with once-daily osimertinib/AZD9291, both of which are ... Clinical data on both

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics